Target Systemic Mastocytosis

Mission Statement

The mission of Target Systemic Mastocytosis (Target SM) is to provide rigorous, comprehensive educational resources about systemic mastocytosis to healthcare professionals who may encounter these patients in their practice. Blueprint Medicines organized and engaged the Target SM Committee, a group of physicians with expertise in systemic mastocytosis that represent a wide range of specialties. Educational resources were developed by Blueprint Medicines in collaboration with the Target SM Committee, and Blueprint Medicines provided funding to the committee for their time and expertise in developing this content.

Clinical Perspectives

What is Systemic Mastocytosis

Systemic mastocytosis is a rare, clonal mast cell neoplasm driven by the KIT D816V mutation in ~95% of patients. In patients with systemic mastocytosis, abnormal mast cell activation and uncontrolled mast cell proliferation result in unpredictable, debilitating symptoms.^1-4

To learn more about systemic mastocytosis, please click the link below and explore the “Systemic Mastocytosis: Disease State Overview” slide module.

References: 1. Vaes M et al. Front Med. 2017;4:110. 2. Jara-Acevedo M et al. Mod Pathol. 2015;28(8):1138-1149. 3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 4. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.

Click To View ►

Clinical Prespectives

What is Systemic Mastocytosis?

Systemic mastocytosis is a rare, clonal mast cell neoplasm driven by the KIT D816V mutation in ~95% of patients. In patients with systemic mastocytosis, abnormal mast cell activation and uncontrolled mast cell proliferation result in unpredictable, debilitating symptoms.^1-4

To learn more about systemic mastocytosis, please click the link below and explore the “Systemic Mastocytosis: Disease State Overview” slide module.

References: 1. Vaes M et al. Front Med. 2017;4:110. 2. Jara-Acevedo M et al. Mod Pathol. 2015;28(8):1138-1149. 3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 4. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.